Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Pre-clinical

Marvel BiosciencesTSXV: MRVL

1 Drug Candidate

Marvel Biosciences is a Calgary-based clinical-stage biotechnology company pursuing a 'drug redevelopment' strategy to create synthetic derivatives of approved drugs with improved therapeutic profiles. Its lead candidate MB-204, a fluorinated derivative of the adenosine A2a receptor antagonist Istradefylline, is advancing through IND-enabling pre-clinical studies targeting autism spectrum disorder, Rett syndrome, and depression, with Phase 1 trials expected to begin in Australia.

Drug Pipeline

1

MB-204

Pre-clinical
Autism Spectrum Disorder (ASD)Depressive Disorders

Fluorinated derivative of Istradefylline (adenosine A2a antagonist); also developing tryptamine derivatives with antidepressant and non-hallucinogenic activity. IND-enabling toxicology complete, Phase 1 planned in Australia.

Quick Facts

Type
Public Biotech
Ticker
TSXV: MRVL
Lead Stage
Pre-clinical
Website
Visit